First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
Fong K, Zhao J, Sultana R, Lee J, Lee S, Chan S, Yau T, Tai D, Sundar R, Too C. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. Liver Cancer 2022, 12: 7-18. PMID: 36872922, PMCID: PMC9982345, DOI: 10.1159/000526639.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaProgression-free survivalFirst-line systemic therapyBarcelona Clinic Liver CancerNetwork meta-analysisOverall survivalStandard of careAlpha-fetoproteinHazard ratioOS benefitSystemic therapyFirst-lineHepatocellular carcinomaFirst-line combination therapyRandom-effects network meta-analysisCombination of atezolizumabInhibitor monoclonal antibodiesFirst-line therapyCochrane Controlled Register of TrialsMeta-analysisKaplan-Meier curvesIndividual patient-level dataCochrane Controlled RegisterRegister of TrialsExtrahepatic spreadPrevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Peng S, Ying A, Chan N, Sundar R, Soon Y, Bandla A. Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Frontiers In Oncology 2022, 12: 731223. PMID: 35186722, PMCID: PMC8853097, DOI: 10.3389/fonc.2022.731223.Peer-Reviewed Original ResearchOxaliplatin-induced peripheral neuropathyNon-pharmacological interventionsChronic oxaliplatin-induced peripheral neuropathyMeta-analysisSystematic reviewPrevent oxaliplatin-induced peripheral neuropathyGrading of RecommendationsPreventive measuresPooled risk ratioQuality of lifeRandomized controlled trialsPrimary outcome measureRandom-effects modelDatabases PubMed-MEDLINENetwork meta-analysisPreventive interventionsOutcome measuresNo interventionPubMed-MedlinePeripheral neuropathyClinical impactRisk ratioControlled trialsCancer patientsConfidence intervals